LB Pharmaceuticals Inc (Nasdaq: LBRX) is a clinical-stage biopharmaceutical company headquartered at One Pennsylvania Plaza, New York, developing novel therapies for neuropsychiatric diseases including schizophrenia and bipolar depression. Its lead asset, LB-102, is an oral small-molecule benzamide antipsychotic with potent D2, D3 and 5HT7 antagonism, positioned to become the first benzamide antipsychotic approved for neuropsychiatric disorders in the United States. The company reported positive Phase 2 schizophrenia results from its NOVA1 trial in January 2025 and initiated the ILLUMINATE-1 Phase 2 bipolar depression trial in January 2026. LB Pharmaceuticals is a drug developer, not a software vendor: it publishes no public API, developer portal, SDK or machine-readable contract, and its web presence is a WordPress corporate and investor-relations site.
LB Pharmaceuticals is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Life Sciences, and Health.
LB Pharmaceuticals’ developer surface includes support and 3 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: lb-pharmaceuticals
name: LB Pharmaceuticals
description: 'LB Pharmaceuticals Inc (Nasdaq: LBRX) is a clinical-stage biopharmaceutical company headquartered at One Pennsylvania
Plaza, New York, developing novel therapies for neuropsychiatric diseases including schizophrenia and bipolar depression.
Its lead asset, LB-102, is an oral small-molecule benzamide antipsychotic with potent D2, D3 and 5HT7 antagonism, positioned
to become the first benzamide antipsychotic approved for neuropsychiatric disorders in the United States. The company reported
positive Phase 2 schizophrenia results from its NOVA1 trial in January 2025 and initiated the ILLUMINATE-1 Phase 2 bipolar
depression trial in January 2026. LB Pharmaceuticals is a drug developer, not a software vendor: it publishes no public
API, developer portal, SDK or machine-readable contract, and its web presence is a WordPress corporate and investor-relations
site.'
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
image: https://lbpharma.us/wp-content/uploads/2026/03/LBlogo-color_final-opt.png
url: https://raw.githubusercontent.com/api-evangelist/lb-pharmaceuticals/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
specificationVersion: '0.20'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Health
- Clinical Trials
- Neuroscience
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/lb-pharmaceuticals-domain-security.yml
- type: Website
url: https://lbpharma.us/
- type: PrivacyPolicy
url: https://lbpharma.us/privacy-policy/
- type: Support
url: https://lbpharma.us/contact/
x-enrichment:
date: '2026-08-23'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: LB Pharmaceuticals is a clinical-stage drug developer whose entire web presence is a WordPress marketing and investor-relations
site; the only machine-readable surface is the stock WordPress core REST API at lbpharma.us/wp-json/ (222 routes, every
namespace a CMS plugin such as contact-form-7, redirection and wp-smush), with no product API, no developer or docs subdomain
(api./docs./developer.lbpharma.us all NXDOMAIN), no GitHub organization and no published client library.
evidence:
- url: https://lbpharma.us/wp-json/
status: 200
- url: https://lbpharma.us/openapi.json
status: 404
- url: https://lbpharma.us/.well-known/agent-card.json
status: 404
- url: https://api.github.com/orgs/lbpharma
status: 404
checked: '2026-08-23'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →